No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)

BACKGROUND: The progressive phase of multiple sclerosis (MS) is characterized by an intrathecal (IT) compartmentalization of inflammation, involving B-cells within meningeal follicles, and resisting all the available immunosuppressive treatments. A new therapeutic paradigm may be to target this infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnan, Mickael, Ferrari, Sylvie, Courtade, Henri, Money, Paul, Desblache, Pauline, Barroso, Bruno, Debeugny, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7964121/
https://www.ncbi.nlm.nih.gov/pubmed/33763241
http://dx.doi.org/10.1155/2021/8813498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7964121/
https://www.ncbi.nlm.nih.gov/pubmed/33763241
http://dx.doi.org/10.1155/2021/8813498

Ejemplares similares